PNI及HGB评估中晚期非小细胞肺癌患者预后的临床价值

doi:10.6040/j.issn.1671-7554.0.2016.1285

摘要/Abstract

摘要： 目的探讨预后营养指数(PNI)及血红蛋白(HGB)评估中晚期非小细胞肺癌患者预后的临床价值。方法选取2013年8月至2015年8月首次确诊的、符合本研究条件的中晚期非小细胞肺癌患者的临床资料;通过电子病历系统、门诊及电话等方法对所有患者进行随访,随访截止到患者死亡或2016年8月;根据PNI中位数(46.52)及HGB中位数(115 g/L)将患者分为高PNI组、低PNI组及高HGB组、低HGB组;通过单因素及多因素分析PNI及HGB对患者总生存期(OS)的影响;制作两组患者的Kaplan-Meier生存曲线,同时行Log-rank检验。通过单因素分析PNI及HGB相关影响因素。结果单因素变量分析示首次确诊时年龄≥65岁、吸烟指数≥400、PNI<46.52、HGB<115 g/L的患者OS明显低于年龄<65岁、吸烟指数<400、PNI≥46.52、HGB≥115 g/L的患者OS(P<0.05);PNI与患者年龄、临床分期、胸腔积液及吸烟指数密切相关(P<0.05);HGB与患者年龄、体质量下降率密切相关(P<0.05)。多因素分析示仅PNI及HGB对患者OS的影响有统计学意义［Exp(B)=2.180, P<0.001;Exp(B)=2.032, P=0.001］。绘制Kaplan-Meier生存曲线同时行Log-rank检验示,高PNI组与低PNI组患者、高HGB组与低HGB组患者OS差异有统计学意义(P<0.001)。结论 PNI及HGB可作为中晚期非小细胞肺癌患者预后的独立危险因素。

关键词: 血红蛋白, 预后, 危险因素, 预后营养指数, 非小细胞肺癌

Abstract: Objective To explore the clinical value of prognosis of nutrition index(PNI)and hemoglobin(HGB)in evaluating the prognosis of the middle to late stage non-small cell lung cancer patients. Methods A total of 120 cases of the middle to late stage non-small cell lung cancer patients were selected during August 2013 and August 2015. The clinical information and data of all patients were collected when they were first confirmed. All patients were followed-up by the date of death or August 2016 through electronic medical record system, outpatient and telephone, etc. The patients were divided into high and low PNI groups, and high and low HGB groups on the basis of the medians of PNI(46.52)and HGB(115 g/L). The impact of PNI and HGB on overall survival(OS)of patients was analyzed through single factor and multiple factors methods. The survival curves of two groups were produced by Kaplan-Meier method. The Log-rank test was exerted. The related influencing factors of PNI and HGB were analyzed through single factor method. Results The single factor analysis showed that the patients with age≥65 years, smoking index≥400, PNI<46.52, HGB<115 g/L when they were first confirmed had significantly lower OS than those with age<65 years, 山东大学学报 (医学版)55卷4期 -孙启晶,等.PNI及HGB评估中晚期非小细胞肺癌患者预后的临床价值 \=-smoking index<400, PNI≥46.52, HGB≥115 g/L(P<0.05). PNI were closely related to the age, clinical stages, pleural effusion and smoking index(P<0.05). HGB were closely related to the age and weight loss rate(P<0.05). The multiple factors analysis showed that only PNI and HGB were statistically significant on OS of the patients［Exp(B)=2.180, P<0.001; Exp(B)=2.032, P=0.001］. The survival curves and Log-rank test showed that low PNI and HGB groups had lower OS than high PNI and HGB groups(P<0.001). Conclusion PNI and HGB can be used as the independent risk factors for the middle to late stage non-small cell lung cancer patients.

Key words: Risk factors, Prognosis of nutrition index, Hemoglobin, Non-small cell lung cancer, Prognostic

中图分类号:

R734

孙启晶,陈方方,李春晓,张才擎. PNI及HGB评估中晚期非小细胞肺癌患者预后的临床价值[J]. 山东大学学报（医学版）, 2017, 55(4): 55-59.

SUN Qijing, CHEN Fangfang, LI Chunxiao, ZHANG Caiqing. Clinical value of PNI and HGB in evaluating the prognosis of the middle to late stage non-small cell lung cancer patients[J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2017, 55(4): 55-59.

参考文献

[1] Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013[J]. CA Cancer J Clin, 2013, 63(1): 11-30.
[2] Jones CD, Cummings IG, Shipolini AR, et al. Does surgery improveprognosis in patients with small-cell lung carcinoma?[J]. Interact Cardiovasc Thorac Surg, 2013, 16(3): 375-380.
[3] Tartari RF, Ulbrich-Kulczynski JM, Filho AF. Measurement of mid-arm muscle circumference and prognosis in stage Ⅳnon-small cell lung cancer patients[J]. Oncol Lett, 2013, 5(3): 1063-1067.
[4] Onodera T, Goseki N, Kosaki G. Prognostic nutritional index in gastrointestinal surgery of malnourished cancer patients[J]. Nihon Geka Gakkai Zasshi, 1984, 85(9): 1001-1005.
[5] Yao ZH, Tian GY, Wan YY, et al. Prognostic nutritional index predicts outcomes of malignantpleural mesothelioma[J]. Cancer Res Clin Oncol, 2013, 139(12): 2117-2123.
[6] Wigren T, Oksanen H, Kellokumpu-Lehtinen P. A practical prognostic index for inoperable non-small-cell lung cancer[J]. Cancer Res Clin Oncol, 1997, 123(5): 259-266.
[7] Harrison LB, Chadha M, Hill RJ, et al. Impact of tumor hypoxia and anemia on radiation therapy outcomes[J]. Oncologist, 2002, 7(6): 492-508.
[8] Migita K, Takayama T, Saeki K, et al. The prognostic nutritional index predicts long-term outcomes of gastric cancer patients independent of tumor stage[J]. Ann Surg Oncol, 2013, 20(8): 2647-2654.
[9] 钱桂生.肺癌不同病理类型发病率的变化情况及其原因[J].中华肺部疾病杂志(电子版), 2011, 4(1): 1-6. QIAN Guisheng. The incidence and reasons for the changes of different pathological types of lung cancer[J]. Clin J Lung Dis(Electronic Edition), 2011, 4(1): 1-6.
[10] de Marinis F, Rossi A, Di Maio M, et al. Treatment of advanced non-small-cell lung cancer: Italian Association of Thoracic Oncology(AIOT)clinical practice guidelines[J]. Lung Cancer, 2011, 73(1): 1-10.
[11] Crinò L, Weder W, van Meerbeeck J, et al. ESMO Guidelines Working Group: early stage and locally advanced(non-metastatic)non-small-cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up[J]. Ann Oncol, 2010, 7(21): v103- v115.
[12] Jemal A, Bray F, Center MM, et al. Global cancerstatistics[J]. CA Cancer J Clin, 2011, 61(2): 69-90.
[13] Alexiou C, Onyeaka CV, Beggs D, et al. Do women live longer followinglung resection for carcinoma?[J]. Eur J Cardiothorac Surg, 2002, 21(2): 319-325.
[14] Coussens LM, Werb Z. Inflammation and cancer[J]. Nature, 2002, 420(6917): 860-867.
[15] Mantovani A, Allavena P, Sica A, et al. Cancer-related inflammation[J]. Nature, 2008, 454(7203): 436-444.
[16] Roxburgh CS, McMillan DC. Role of systemic inflammatory response in predicting survival in patients with primary operative cancer[J]. Future Oncol, 2010, 6(1): 149-163.
[17] Proctor MJ, Morrison DS, Talwar D, et al. A Glasgow inflammation outcome study[J]. Eur J Cancer, 2011, 47(17): 2633-2641.
[18] Qiu C, Qu X, Shen H, et al. Evaluation of prognostic nutritional index in patients undergoing radical surgery with nonsmall cell lung cancer[J]. Nutr Cancer, 2015, 67(5): 741-747.
[19] Chamogeorgakis T, Anagnostopoulos C, Kostopanagiotou G, et al. Does anemia affect outcome after lobectomy or pneumonectomy in early stage lung cancer patients who have not received neo-adjuvant treatment?[J]. Thorac Cardiovasc Surg, 2008, 56(3): 148-153.
[20] Tomita M, Shimizu T, Hara M, et al. Impact of preoperative hemoglobin level on survival of non-small cell lungcancer patients[J]. Anticancer Res, 2008, 28(3): 1947-1950.
[21] MacRae R, Shyr Y, Johnson D, et al. Declining hemoglobinduring chemoradiotherapy for locally advanced non-small celllung cancer is significant[J]. Radiother Oncol, 2002, 64(1): 37-40.
[22] Hsu CL, Chen KY, Shih JY, et al. Advanced non-small cell lung cancer in patients aged 45 years or younger: outcome and prognostic factors[J]. BMC Cancer, 2012, 12: 241.
[23] Merlini L, Carteni G, Iacobelli S, et al. Anemia prevalence and treatment practice in patients with non-myeloid tumors receiving chemotherapy[J]. Cancer Manag Res, 2013, 2(5): 205-214.
[24] 郝静,王秀问,蔡毅然,等.在非小细胞肺癌中急、慢性乏氧标记物HIF-1α、GLUT1表达的临床意义[J].山东大学学报(医学版),2005,43(8): 756-759. HAO Jing, WANG Xiuwen, CAI Yiran, et al. Expressions of HIF-1α and GLUT1 and their clinical significance in non-small cell lung cancer[J]. Journal of Shandong University(Healthy Sciences), 2005, 43(8): 756-759.
[25] Calabrich A, Katz A. Management of anemia in cancer patients[J]. Future Oncol, 2011, 7(4): 507-517.

相关文章 15

[1]	黄玉真,吕琛,颜磊,李帅帅,张景雪,刘超,王银霞,桑岩岩,房鹛. 基于危险因素筛查的延续性院外管理对卵巢过度刺激综合征的预防效果[J]. 山东大学学报 (医学版), 2026, 64(4): 92-99.
[2]	黄佩文, 王旭东. 治疗非小细胞肺癌新药:靶向c-Met蛋白的抗体药物偶联物Telisotuzumab Vedotin[J]. 山东大学学报 (医学版), 2026, 64(3): 124-130.
[3]	逄锦宏,苏萍,乔俊鹏,陈巧巧,陈学禹,赵颖颖,施婕,孙晓茹,李秋春,何蕊言,范轶欧,迟蔚蔚. 老年人群可改变心血管危险因素聚集模式与脑卒中的关联[J]. 山东大学学报 (医学版), 2025, 63(9): 11-19.
[4]	李梓绮,魏闫若雪,刘晓晗,刘春铖,赵然,刘玉昆. 长链非编码RNA HEATR3反义RNA 1参与结直肠癌发生发展的功能及其临床意义[J]. 山东大学学报 (医学版), 2025, 63(9): 108-115.
[5]	张政,王建伟,杨玉娟,张宇,宋西成. 哮喘儿童2008及2019年免疫球蛋白E变化及相关危险因素[J]. 山东大学学报 (医学版), 2025, 63(7): 32-36.
[6]	刘保国,宋翔,赵晓文,毛亚丽. 血清STAT5B、NKAIN1 mRNA检测在乳腺癌中的应用价值[J]. 山东大学学报 (医学版), 2025, 63(7): 68-74.
[7]	王磊,常霄,王梓萌,李娇娇,崔书君,杨飞,朱月香. 瘤内及瘤周DCE-MRI影像组学对宫颈癌患者无进展生存期的预测价值[J]. 山东大学学报 (医学版), 2025, 63(6): 45-54.
[8]	贾若曦,吕丽,刘涵云,吴寅平,李凤彩,赵泽华,王凯,范玉琛. 血细胞计数相关标志物对慢加急性乙型肝炎肝衰竭患者28天预后的诊断价值[J]. 山东大学学报 (医学版), 2025, 63(6): 89-99.
[9]	赵汉卿,周新睿,李子建,唐兴. 循环肿瘤细胞联合血清学检测在非小细胞肺癌中的应用[J]. 山东大学学报 (医学版), 2025, 63(5): 79-85.
[10]	杜雪,李春霞,刘云霞,张涛. 基于MFPC-Cox的结直肠癌患者预后动态预测模型[J]. 山东大学学报 (医学版), 2025, 63(5): 101-110.
[11]	李敬,郝盼盼. 急性心力衰竭患者出入院心率变化与预后相关性[J]. 山东大学学报 (医学版), 2025, 63(4): 75-82.
[12]	杨卫芳,徐宏,刘元涛,赵蕙琛. 促甲状腺激素受体抗体在Graves病复发中的作用机制及其临床意义[J]. 山东大学学报 (医学版), 2025, 63(4): 116-121.
[13]	徐年兴,魏东,乔俊杰,战炳炎. CD8⁺、IL-6和PaO₂对不可切除Ⅲ_B/C和Ⅳ期非小细胞肺癌免疫治疗触发放射召回性肺炎的预测价值[J]. 山东大学学报 (医学版), 2025, 63(2): 29-35.
[14]	山东省腔镜外科质量控制中心胸腔镜委员会. 山东省VATS/RATS非小细胞肺癌围术期质量控制指标专家共识(2025版)[J]. 山东大学学报 (医学版), 2025, 63(12): 1-5.
[15]	程震宇,来庆国,吴梦涛. 髂股静脉支架置入术后再狭窄的影响因素研究进展[J]. 山东大学学报 (医学版), 2025, 63(12): 112-117.

多维度评价

Viewed

Full text

Abstract

Cited

Shared

Discussed